Thomas Waldmann

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. Ji Y, Wrzesinski C, Yu Z, Hu J, Gautam S, Hawk N, et al. miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines. Proc Natl Acad Sci U S A. 2015;112:476-81 pubmed publisher
  2. Zhang M, Mathews Griner L, Ju W, Duveau D, Guha R, Petrus M, et al. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. Proc Natl Acad Sci U S A. 2015;112:12480-5 pubmed publisher
    ..These studies provide support for a therapeutic trial in patients with smoldering/chronic ATL using a drug combination that inhibits JAK signaling and antiapoptotic protein Bcl-xL. ..
  3. Waldmann T, Chen J. Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. Annu Rev Immunol. 2017;35:533-550 pubmed publisher
  4. Nakagawa M, Shaffer A, Ceribelli M, Zhang M, Wright G, Huang D, et al. Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma. Cancer Cell. 2018;34:286-297.e10 pubmed publisher
    ..Our study demonstrates that the HTLV-I oncogenic retrovirus exploits a regulatory module that can be attacked therapeutically with BET inhibitors. ..
  5. request reprint
    Waldmann T. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol. 2007;27:1-18 pubmed
  6. Waldmann T, Lugli E, Roederer M, Perera L, Smedley J, Macallister R, et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood. 2011;117:4787-95 pubmed publisher
  7. Waldmann T, Conlon K, Stewart D, Worthy T, Janik J, Fleisher T, et al. Phase 1 trial of IL-15 trans presentation blockade using humanized Mik?1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood. 2013;121:476-84 pubmed publisher
  8. Waldmann T. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res. 2015;3:219-27 pubmed publisher
    ..Furthermore, clinical trials are being initiated that employ the combination of IL15 with IL15Rα(+/-) IgFc. ..
  9. Janik J, Morris J, O Mahony D, Pittaluga S, Jaffe E, Redon C, et al. 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma. Proc Natl Acad Sci U S A. 2015;112:13045-50 pubmed publisher
    ..In conclusion, repeated (90)Y-daclizumab infusions directed predominantly toward nonmalignant T cells rosetting around Reed-Sternberg cells provided meaningful therapy for select HL patients. ..

More Information

Publications16

  1. Berkowitz J, Janik J, Stewart D, Jaffe E, Stetler Stevenson M, Shih J, et al. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin Immunol. 2014;155:176-87 pubmed publisher
    ..g., multiple sclerosis) since high-dose daclizumab is required to saturate IL-2R alpha in extravascular sites. ..
  2. Conlon K, Lugli E, Welles H, Rosenberg S, Fojo A, Morris J, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2015;33:74-82 pubmed publisher
    ..To reduce toxicity and increase efficacy, alternative dosing strategies have been initiated, including continuous intravenous infusions and subcutaneous IL-15 administration. ..
  3. request reprint
    Waldmann T. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6:595-601 pubmed
    ..As discussed in this Review, the biology of these cytokines will affect the development of novel therapies for malignancy and autoimmune diseases, as well as the design of vaccines against infectious diseases. ..
  4. Ju W, Zhang M, Wilson K, Petrus M, Bamford R, Zhang X, et al. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma. Proc Natl Acad Sci U S A. 2016;113:1624-9 pubmed publisher
    ..These studies provide scientific support for a clinical trial to evaluate BV combined with ruxolitinib in select patients with HL. ..
  5. Sharma K, Janik J, O Mahony D, Stewart D, Pittaluga S, Stetler Stevenson M, et al. Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma. Clin Cancer Res. 2017;23:35-42 pubmed publisher
    ..These studies support inclusion of alemtuzumab in novel multidrug therapies for ATL. Clin Cancer Res; 23(1); 35-42. ©2016 AACR. ..
  6. Waldmann T. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics. Mol Cell Endocrinol. 2017;451:66-70 pubmed publisher
  7. Chen J, Zhang Y, Petrus M, Xiao W, Nicolae A, Raffeld M, et al. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. Proc Natl Acad Sci U S A. 2017;114:3975-3980 pubmed publisher
    ..Therefore, JAK inhibitor therapy might benefit patients with ALK- ALCL who are phosphorylated STAT3<sup/>. ..